Yamada K, Shiomi T, Momose H, Yamamoto M, Okamura K, Suemori T
Hinyokika Kiyo. 1985 May;31(5):901-6.
Long-term therapeutic effect of Robaveron tablet (KN-7) was studied on 10 female patients of middle and old age with ptosis of urinary bladder and 9 patients with neurogenic bladder. The patients had mainly complained of such subjective symptoms as pollakisuria, difficulty of urination, sense of residual urine, lower abdominal discomfort and urinary incontinence. Robaveron tablet was administered at 2 tablets t.i.d. for 3-26 months. And the drug efficacy was evaluated by residual urine, cystometric findings and subjective symptoms. A significant decrease in the residual urine rate and a significant increase of pressure amplitude were obtained, and improvement of subjective symptoms was seen with an effective rate of about 70%. Overall effectiveness, rated slightly improved or better was 89.5%. No cases of side effects or abnormalities in laboratory tests were observed. Robaveron tablet is safe and effective for patients with urinary disturbance accompanied by ptosis of urinary bladder, as a myogenic disorder, as well as neurogenic bladder in the long-term therapy.
对10例中老年膀胱脱垂女性患者和9例神经源性膀胱患者研究了罗巴弗龙片(KN-7)的长期治疗效果。患者主要主诉有尿频、排尿困难、残余尿感、下腹部不适和尿失禁等主观症状。罗巴弗龙片每次2片,每日3次,服用3 - 26个月。通过残余尿量、膀胱测压结果和主观症状评估药物疗效。残余尿率显著降低,压力幅度显著增加,主观症状改善,有效率约为70%。总体有效率(评定为稍有改善或更好)为89.5%。未观察到副作用或实验室检查异常的病例。罗巴弗龙片对于伴有膀胱脱垂(作为一种肌源性疾病)以及神经源性膀胱的排尿障碍患者进行长期治疗是安全有效的。